Key takeaways
Ubrelvy (ubrogepant) and Relpax (eletriptan) are both medications used to treat migraine attacks with or without aura in adults. However, they belong to different medication classes. Ubrelvy is a calcitonin gene-related peptide (CGRP) receptor blocker, while Relpax is a triptan. Ubrelvy is taken as a 50 mg or 100 mg oral dose, with a second dose possible after 2 hours if needed, but not exceeding 200 mg per day. Relpax is taken as a 20 mg or 40 mg oral dose, with a second dose possible after 2 hours, but not exceeding 80 mg per day. Ubrelvy is not available as a generic, while Relpax is available in a lower-cost generic form. Common side effects of Ubrelvy include nausea, sleepiness, and dry mouth, whereas Relpax can cause dizziness, sleepiness, and nausea. Ubrelvy interacts with many medications, including certain antibiotics and seizure medications, while Relpax has serious interactions with ergot-containing medications and other triptans. Additionally, Relpax is not typically recommended for people with certain heart conditions or high blood pressure.
